Market Fallout From the EPA's Rush Decision
The Environmental Protection Agency is moving quickly to finalize 2025 emission standards.
Hertz Blinks First With Car Rental Marching Toward Abyss
Hertz's deal with Lyft highlights the direction the industry must move in to survive.
Welcome to Prime Time, Driverless Cars
The Alphabet vs. Apple battle, the Tesla Model X release, and the VW diesel scandal highlight an industry at an inflection point.
3 Key Developments for Autonomous Cars
The mobility revolution moves ahead full steam.
Cheap Car Rental Stocks Are a Bad Idea
This is a business model prime for disruption and will bring value-seeking investors nothing but misery.
Top Stocks to Invest in Autonomous Cars
These two hidden investment ideas have tremendous upside potential.
The Self-Driving Car and the Future of Mobility
A revolution in how we travel is nearly upon us.
5 Investing Lessons from NFL Free Agency
Winning NFL roster construction has direct parallels to smart investing
After Apple: Tech's Takeover of Healthcare Officially Begins
Ebola is spreading, new diabetes and obesity drugs, and Apple and Google move into healthcare, because this is where the money is.
Ebola Vaccine and Inhaled Insulin Incoming
Biotech partnerships, an IPO that wasn't, and how big data is fighting Ebola.
3 Key Takeaways from Biogen Idec Inc Stock's Earnings Annihilation
An executive summary of a monster quarter
Herbalife Says "I Think I-Cahn" as Short-Sellers Go "Ack, Man"
Pershing Square's Bill Ackman's scathing presentation sends Herbalife shares soaring
ISIS Pharmaceuticals, Inc. is The Best Stock Today
The Motley Fool readers made their voices heard as it wins a 32 stock tournament
Why the Market is Wrong about Johnson & Johnson
Todays sell-off at odds with second quarter results and guidance update
1 Special Situation Dividend Stock: Snatch Up of Stay Away?
Is the Theravance split may be a buying opportunity or a dividend chasing mistake?
Should Dividend Investors Keep or Eject Bristol-Myers Squibb Co?
World Cup mania and dividend stocks collide
Is Europe Igniting Eli Lilly's Comeback?
The CHMP recommends approval for Lantus biosimilar insulin
A Big Pharma Sex Tape Compounds China Woes
GlaxoSmithKline's troubles in China just won't go away
How Obamacare Exchange Innovation Can Go Wrong
The tech industy's disruptive model may not work for insurance customers
1 Key Question Remains after MannKind's Giant Leap
After FDA approval, now comes the hard part